Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Oral Doses of BI 1291583 qd Versus Placebo in Healthy Male and Female Subjects for 4 Weeks (Single-blind, Partially Randomised, Placebo-controlled Parallel Group Design)
Latest Information Update: 25 Jul 2022
At a glance
- Drugs BI 1291583 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 06 Dec 2021 Status changed from active, no longer recruiting to completed.
- 02 Nov 2021 Planned End Date changed from 19 Nov 2021 to 22 Nov 2021.
- 02 Nov 2021 Planned primary completion date changed from 19 Nov 2021 to 22 Nov 2021.